期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

唑来磷酸对阿那曲唑致乳腺癌患者骨量减少的抑制作用 被引量：2

Inhibitory effect of zoledronic acid on anastrozole-induced osteopenia in breast cancer patients
原文传递
导出
摘要 目的观察唑来磷酸对绝经后乳腺癌患者应用阿那曲唑内分泌治疗导致骨量减少的影响。方法绝经后雌激素受体阳性乳腺癌患者53例,在应用钙剂联合维生素D3制剂基础上分别采用唑来磷酸联合阿那曲唑(治疗组,23例)和阿那曲唑(对照组,30例)治疗。用药方法:唑来磷酸4mg/28d静脉滴注,阿那曲唑1mg/d口服。观察治疗前和治疗6、12、18个月骨密度(BMD)变化。结果与治疗前比较,治疗期治疗组BMD明显升高(P<0.05),而对照组BMD无明显变化(P>0.05)。结论加用唑来磷酸治疗能明显防止绝经后乳腺癌患者阿那曲唑引起的骨量减少作用。 Objective To investigate the influence of zoledronic acid on anastrozole-induced osteopenia in postmenopausal women with breast cancer. Methods On the basis of routine calcium plus vitamin D3 treatment, 53 patients with postmenopausal estrogen receptor-positive breast cancer were treated with ananstrozle and zoledronic acid（group A, 23 cases） and with ananstrozle（group B, 30 cases）. Zoledronic acid 4 mg was infused onece every 4 weeks and oral ananstrozle 1 mg/d was used. The changes in bone mineral density（BMD） of lumbar spine and hip bone were followed up in the 6th, 12th and 18th month during treatment. Results Compared to before, BMD was higher during treatment in group A （P^0. 05 ）, which was not significantly changed in group B （P〉0. 05 ）. Conclusion Adding zoledronic acid therapy can effectively prevent anastrozole-induced osteopenia in postmenopausal women with breast cancer.
作者 王汉晋 胡云 周萍 朱春花 黄敏
机构地区 南京医科大学附属南京医院普通外科
出处 《江苏医药》 CAS 北大核心 2013年第23期2845-2847,共3页 Jiangsu Medical Journal
基金 南京医科大学科技发展基金重点项目(08NMUZ038)
关键词 唑来磷酸 骨密度 阿那曲唑 乳腺癌 Zoledronic acid Bone mineral density Anastrozole Breast cancer
分类号 R737 [医药卫生—肿瘤]
  • 相关文献

参考文献8

  • 1Eastell R, Hannon RA, Cuziek J, et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)[J]. J Bone Miner Res, 2006, 21 (8),1215-1223.
  • 2Smith MR, McGovem FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for Drostate cancer[J]. N Engl J Med, 2001,345 (13), 948-955.
  • 3李煜明,崔维顶,吴斌,吴蓉.唑来磷酸联合普伐他汀治疗大鼠骨质疏松[J].江苏医药,2009,35(3):316-318. 被引量：1
  • 4Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphospho nates in solid tumours: recommendations of an international expert panel[J]. Ann Oncol, 2008,19 ( 3 ) : 420-432.
  • 5Mystakidou K, Katsouda E, Parpa E, et al. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline [J], Med Oncol, 2005,22 (2) : 195-201.
  • 6Brufsky A. Management of cancer-treatment-induced bone loss in postmenopau sal women undergoing adjuvant breast cancer therapy: a Z-FAST up date[J]. Semin Oncol, 2006,33 (2 Suppl 7) : S13-S17.
  • 7Amadori D, Aglietta M, Alessi B, et al. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treat- ment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial[J]. Lancet Oncol, 2013,14(7) : 663-670.
  • 8Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results[J]. Ann Oncol, 2013,24(2) : 398-405.

二级参考文献10

  • 1Fahrleitner Pammer A, Dobnig H, Piswanger Selkner C, et al. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status[J]. Wien Klin Woehenschr,2003, 115(9): 291-297.
  • 2Miyazaki T, Matsunaga T, Miyazaki S, et al. Changes in receptor activator of nuclear faclor kappa B, and ils ligand, osteoprotegerin, bone lype alkaline phosphatase, and tartrateresistant acid phosphatase in owariectomized rats [J]. J Cell Biochem, 2004, 93 ( 3 ) : 503-512.
  • 3Viereck V, Emons G, Lauck V, et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts[J]. Biochem Biophys Res Commun,2002,291(3) :680-686.
  • 4Myoung H, Park J Y,Choung PH. Effects of a bisphosphonate on the expression of bone specific genes after autogenous free bone grafting in rats[J]. J Periodontal Res,2001,36(4 ) : 244- 251.
  • 5Pan B, Farrugia AN, To LB, et al. The nitrogen containing bisphosphonate, zoledronic acid, influences RANKI.expression in human osteoblasl like cells by activating TNFalpha converting enzyme (TACE)[J].J Bone Miner Res,2004,19(1):147 154.
  • 6Mundy G,Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins[J].Science, 1999, 286(5446) : 1946-1949.
  • 7Maeda T, Matsunuma A, Kawane T, et al. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3 E1 cells[J]. Biochem Biophys Res Commun, 2001, 280(3) :874-877.
  • 8Ohnaka K,Shimoda S, Nawata H, et al. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts[J].Biochem Biophys Res Cmmun,2001,287(2):337-342.
  • 9Kaji H, Kanatani M, Sugimoto T, et al. Statins modulate the levels of osteoprotegerin/receptor activator of NF kappa B ligand mRNA in mouse bone cell cuhures[J].Horm Metab Res,2005,37(10) :589-592.
  • 10Wang J W, Xu SW, Yang DS, et al. Locally appplied simvastatin promotes fracture healing in owlrieclomized rat[J].Osteoporos Int,2007,18(12) : 1641-1650.

同被引文献28

二级引证文献19

江苏医药
2013年 第23期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部